[{"orgOrder":0,"company":"Smartbax","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Smartbax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Smartbax \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Smartbax \/ Boehringer Ingelheim GmbH"}]

Find Clinical Drug Pipeline Developments & Deals by Smartbax

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PEGS Boston Summit
                          Not Confirmed
                          PEGS Boston Summit
                          Not Confirmed

                          Details : The funds will be used to advance smartbax’s small molecule antibiotics through preclinical studies, expand the company’s scientific team to further develop its innovative research platforms and identify novel solutions against multi-drug resistant p...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 23, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : $1.2 million

                          Deal Type : Financing

                          blank